| Literature DB >> 21876034 |
Aradhana Rani1, Behdad Afzali, Audrey Kelly, Lemlem Tewolde-Berhan, Mark Hackett, Aditi S Kanhere, Isabela Pedroza-Pacheco, Holly Bowen, Stipo Jurcevic, Richard G Jenner, David J Cousins, Jack A Ragheb, Paul Lavender, Susan John.
Abstract
Blockade of IL-2R with humanized anti-CD25 Abs, such as daclizumab, inhibits Th2 responses in human T cells. Recent murine studies have shown that IL-2 also plays a significant role in regulating Th2 cell differentiation by activated STAT5. To explore the role of activated STAT5 in the Th2 differentiation of primary human T cells, we studied the mechanisms underlying IL-2 regulation of C-MAF expression. Chromatin immunoprecipitation studies revealed that IL-2 induced STAT5 binding to specific sites in the C-MAF promoter. These sites corresponded to regions enriched for markers of chromatin architectural features in both resting CD4 and differentiated Th2 cells. Unlike IL-6, IL-2 induced C-MAF expression in CD4 T cells with or without prior TCR stimulation. TCR-induced C-MAF expression was significantly inhibited by treatment with daclizumab or a JAK3 inhibitor, R333. Furthermore, IL-2 and IL-6 synergistically induced C-MAF expression in TCR-activated T cells, suggesting functional cooperation between these cytokines. Finally, both TCR-induced early IL4 mRNA expression and IL-4 cytokine expression in differentiated Th2 cells were significantly inhibited by IL-2R blockade. Thus, our findings demonstrate the importance of IL-2 in Th2 differentiation in human T cells and support the notion that IL-2R-directed therapies may have utility in the treatment of allergic disorders.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21876034 PMCID: PMC3432901 DOI: 10.4049/jimmunol.1002354
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422